Aim: To observe symptom and histologic amelioration of Parkinson disease models transplanted by C17.2 neural stem cells (NSC) modified by adenovirus with NURR1 (Ad-NURR1) gene. Methods: The experiment was performed at the Linbaixin Experimental Center, Second Affiliated Hospital, Sun Yat-sen University from March 2004 to January 2005. SD rat Parkinson disease models were induced by 6-hydroxyl-dopamine in two points injection of half-corpus striatum. One week later, emetomorphine praxiology examination was performed: emetomorphine (0.5 mg/kg) was treated by intraperitoneal injection before within 30 minutes mean cycles of body rotation 360° in a minute was counted. The successful PD models could rotate 6 cycles in a minute, tested once in a week for 4 weeks. Totally 31 stable animal models were obtained. Of them, there were 10 in Parkinson disease model control group, 11 in Parkinson disease plus C17.2 group and 10 in Parkinson disease plus C17.2 plus adenovirus group. C17.2 NSC, C17.2 NSC modified by Ad-NURR1 gene and (1.0-4.0) ×109 L-1 cells were collected sterilely. Parkinson disease models were transplanted with sterile cell injection. The injection point was the same as that during establishing models, about 3 μL. Parkinson disease model control group received saline. After cell transplantation for 10 days and 4 weeks, Parkinson disease model rotation trial induced by emetomorphine was performed. Number of tyrosine hydroxylase positive neurons in striatum of Parkinson disease models was measured with immunohistochemistry. Results: Four rats died during the trial, totally 27 Parkinson disease model rats were involved in the trial. 1 Cycles of rotation of Parkinson disease models: At day 10 and week 4 after transplantation, it was fewer in the Parkinson disease plus C17.2 group and Parkinson disease plus C17.2 plus adenovirus group than that in the Parkinson disease model control group; It was fewer in the Parkinson disease plus C17.2 plus adenovirus group than that in the Parkinson disease plus C17.2 group (10 days after transplantation: 21.57±5.26 in the Parkinson disease model control group, 3.90±0.90 in the Parkinson disease plus C17.2 group, 1.56±0.58 in the Parkinson disease plus C17.2 plus adenovirus group; 4 weeks after transplantation: 18.40±5.84 in the Parkinson disease model control group, 3.60±0.67 in the Parkinson disease plus C17.2 group, 1.00±0.55 in the Parkinson disease plus C17.2 plus adenovirus group, P < 0.05). 2 Number of tyrosine hydroxylase positive cells in striatum: 10 days after transplantation it was more in the Parkinson disease plus C17.2 group and Parkinson disease plus C17.2 plus adenovirus group than that in the Parkinson disease model control group; It was more in the Parkinson disease plus C17.2 plus adenovirus group than that in the Parkinson disease plus C17.2 group (350±0.67 in the Parkinson disease model control group, 13.17±1.89 in the Parkinson disease plus C17.2 group, 20.50±1.,67 in the Parkinson disease plus C17.2 plus adenovirus group, P < 0.05). Conclusion: NURR1 gene combined with NSC can effectively ameliorate PD models symptoms and elevate the number of tyrosine hydroxylase positive neurons after transplantation.